These findings highlight the value of metformin in inhibiting ovarian tumor cells via phosphorylation of the AKT/mTOR pathway, which indeed plays an essential role in the prognosis of ovarian cancer. The gene discussed is AKT1; the disease is ovarian carcinoma.